Five-year survival of stage IIIA-IIIB (non-N3) non-small cell lung cancer patients after platinum/gemcitabine induction chemotherapy and surgery

Andrea Imperatori, D. La Salvia, N. Rotolo, E. Nardecchia, M. Bandera, O. Toungoussova, A. Spanevello, L. Dominioni

Research output: Contribution to journalArticle

Abstract

The 5-year survival rate of marginally resectable non-small cell lung cancer (NSCLC) patients treated by platinum/gemcitabine induction chemotherapy and surgery is not well documented. We studied 47 consecutive patients with NSCLC stage IIIA-IIIB (non-N3) treated with platinum/gemcitabine induction chemotherapy (median: 3 cycles) and evaluated the objective response, resectability, surgical morbidity/mortality and long-term survival rate. The induction chemotherapy was completed by 45/47 patients. Objective response was: 36% partial, 32% stable disease, 28% progression, 0% complete; two patients (4%) died during induction chemotherapy. Tumor resectability was 74%, postoperative morbidity 34%, mortality nil. 26% of patients were unresectable. In the whole cohort the 5-year survival was 25% (95%CI, 17%-32%) and the median survival was 22 months (28 months in resected patients; 7 months in unresectable). In conclusion, in the intention-to-treat population undergoing platinum/gemcitabine induction chemotherapy, resectability was high (74%) and the 5-year survival rate was 25%. Median survival in resected cases was three-fold greater than in the unresected.

Original languageEnglish
Pages (from-to)191-196
Number of pages6
JournalJournal of Chemotherapy
Volume22
Issue number3
Publication statusPublished - Jun 2010

Keywords

  • 5-Year survival
  • Cisplatin
  • Gemcitabine
  • General thoracic surgery
  • Induction therapy
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Oncology
  • Pharmacology

Fingerprint Dive into the research topics of 'Five-year survival of stage IIIA-IIIB (non-N3) non-small cell lung cancer patients after platinum/gemcitabine induction chemotherapy and surgery'. Together they form a unique fingerprint.

  • Cite this

    Imperatori, A., La Salvia, D., Rotolo, N., Nardecchia, E., Bandera, M., Toungoussova, O., Spanevello, A., & Dominioni, L. (2010). Five-year survival of stage IIIA-IIIB (non-N3) non-small cell lung cancer patients after platinum/gemcitabine induction chemotherapy and surgery. Journal of Chemotherapy, 22(3), 191-196.